生物活性：Pazopanib-13C,d3 is the deuterium and 13C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Pazopanib-13C,d3 相关抗体:
FGFR2/CD332 Antibody
c-Kit Antibody (YA502)
Phospho-PDGFR beta (Y740) Antibody
VEGF Receptor 2 Antibody (YA014)
FGFR1 Antibody
FGFR1 Oncogene Partner Antibody
FGFR2 Antibody
FGFR3 Antibody
PDGFR alpha Antibody
FGF2 Antibody
VEGF Receptor 1 Antibody
VEGFA Antibody
VEGF Receptor2 Antibody
FGF1 Antibody (YA1430)
PDGF B Antibody (YA1556)
FGFR4 Antibody (YA1588)
PLGF Antibody (YA1812)
PDGFR beta Antibody (YA1925)
VEGFD Antibody (YA2385)
FGF19 Antibody (YA2672)
TACC3 Antibody (YA2921)
Phospho-PDGFR beta (Tyr740) Antibody (YA3062)
FGF21 Antibody (YA3276)
c-Kit Antibody
SCF Antibody
PGF Antibody (YA1434)
Neuropilin 1 Antibody (YA1831)
VEGFB Antibody (YA2627)
分子量：441.53
Formula：C2013CH20D3N7O2S
CAS 号：1261734-88-6
非标记 CAS：444731-52-6
中文名称：帕唑帕尼-13C,d3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (527 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[2]. Harris PA, et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008, 51(15), 4632-4640.
 [Content Brief]
[3]. Thakur A, et al. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res. 2011 Nov;82(3):346-50.
 [Content Brief]